Watson Pharmaceuticals Financial Statements
Watson Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Watson Pharmaceuticals Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 2,535.5 | 2,496.7 | 1,979.2 |
| Gross Profit ($ mil.) | 1,032.7 | 991.9 | 745.8 |
| Operating Income ($ mil.) | 386.5 | 268.8 | (388.9) |
| Total Net Income ($ mil.) | 238.4 | 141.0 | (445.0) |
| Diluted EPS (Net Income) | 2.09 | 1.27 | (4.37) |
Watson Pharmaceuticals Quarterly Statements
| Quarter Ending Sep 09 | Quarter Ending Jun 09 | Quarter Ending Jun 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 662.1 | 677.8 | 677.8 |
| Gross Profit ($ mil.) | 308.4 | 284.7 | 284.7 |
| Operating Income ($ mil.) | 111.3 | 95.2 | 95.2 |
| Total Net Income ($ mil.) | 63.0 | 53.0 | 53.0 |
| Diluted EPS (Net Income) | 0.55 | 0.46 | 0.46 |
Watson Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.56 | 1.15 | 7.00 |
| Price/Earnings Ratio | 17.92 | 23.87 | 25.45 |
| Price/Book Ratio | 1.59 | 1.72 | 6.74 |
| Price/Cash Flow Ratio | 10.01 | 9.23 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Watson Pharmaceuticals Financial Ratios
Watson Pharmaceuticals Competitive Intelligence
| Barr Pharmaceuticals | Mylan | Teva Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 0.0 | 5,137.6 | 11,085.0 |
| Employees | 8,900 | 15,000 | 38,307 |
| Market Cap ($ mil.) | -- | 5,002.4 | 47,077.4 |
Competitive Landscape
